Clinical Trial Update: Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing 28-day versus 56-day treatment for Pseudomonas aeruginosa in children with cystic fibrosis; results and safety data have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Snippet

Sponsor: Novartis | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2011-08-29